Brief: 2Seventy Bio BBT369 & CBLB Gene Edited Autologous Car T For Non-Hodgkin Lymphoma Showed Edit-Driven T Cell Activity In Multiple Preclinical Models
17/05/2023 12:53
May 17 (Reuters) - 2Seventy Bio Inc TSVT.O :
* 2SEVENTY BIO: BBT369 & CBLB GENE EDITED AUTOLOGOUS CAR T
FOR
NON-HODGKIN LYMPHOMA SHOWED EDIT-DRIVEN T CELL ACTIVITY IN
MULTIPLE PRECLINICAL MODELS
* 2SEVENTY BIO - RESET DISPLAYED MARKEDLY INCREASED
TARGETING
SENSITIVITY AND PHARMACOLOGICALLY CONTROLLED ANTI-TUMOR ACTIVITY
* 2SEVENTY BIO INC - NOVEL TGFΒ SWITCH RECEPTOR DROVE
ENHANCED
MAGE-A4 TCR ANTI-TUMOR ACTIVITY WITH A FAVORABLE SAFETY PROFILE
Source text for Eikon: ID:
Further company coverage: TSVT.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on 2Seventy Bio
See all news2Seventy Bio Inc expected to post a loss of 17 cents a share - Earnings Preview
2Seventy Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: 2Seventy Bio Q4 Basic EPS USD -0.37
2Seventy Bio Inc expected to post a loss of 26 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Elevance, Backblaze, Disney